FindTrial
Sign In

Comparative efficacy and safety of antidiabetic drugs in treating diabetes mellitus

Comparative efficacy and safety of antidiabetic drugs in treating diabetes mellitus - Comparative efficacy and safety of antidiabetic drugs

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000032496
Enrollment
10000
Registered
2018-05-09
Start date
2018-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

None listed

Sponsors

The University of Tokyo
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: New user receiving or dispensed prescription of DPP-4 inhibitors, SGLT-2 inhibitors, and GLP-1 agonists, including fixed-dose combination (FDC) products containing these medication groups T2DM diagnosis on or prior to the index date

Exclusion criteria

Exclusion criteria: Patients with a T1DM diagnosis Patients with gestational diabetes within 1 year before index date

Design outcomes

Primary

MeasureTime frame
Mortality, macrovascular event, microvascular event, dialysis, sepsis, diabetic ketoacidosis, amputation, fracture, and severe hypoglycemia—

Countries

Japan,Asia(except Japan),North America,South America,Australia,Europe,Africa

Contacts

Public ContactTomohide Yamada

The University of Tokyo Health service center

YAMADAT-INT@h.u-tokyo.ac.jp03-5841-2575

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026